MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/00365521.2019.1600014

Медицинская библиотека · Scandinavian journal of gastroenterology · 2019

Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.

Strik Anne S, Löwenberg Mark, Buskens Christianne J, B Gecse Krisztina, I Ponsioen Cyriel, Bemelman Willem A, D'Haens Geert R

СтатьяПеревод пока не подготовлен

Аннотация

Objectives

Anti-TNF agents are effective to treat perianal Crohn's disease (CD). Evidence suggests that Crohn's disease patients with perianal fistulas need higher infliximab (IFX) serum concentrations compared to patients without perianal CD to achieve complete disease control. Our aim was to compare anti-TNF serum concentrations between patients with actively draining and closed perianal fistulas.

Methods

A retrospective survey was performed in CD patients with perianal disease treated with IFX or adalimumab (ADL). Fistula closure was defined as absence of active drainage at gentle finger compression and/or fistula healing on magnetic resonance imaging.

Results

We identified 66 CD patients with a history of perianal fistulas treated with IFX (n = 47) and ADL (n = 19). Median IFX serum trough concentrations ([interquartile range]) were higher in patients with closed fistulas (n = 32) compared to patients with actively draining fistulas (n = 15): 6.0 µg/ml [5.4-6.9] versus 2.3 µg/ml [1.1-4.0], respectively (p < .001)). A similar difference was seen in patients treated with ADL: median serum concentrations were 7.4 µg/ml [6.5-10.8] in 13 patients with closed fistulas versus 4.8 µg/ml [1.7-6.2] in 6 patients with producing fistulas (p = .003). Serum concentrations of ≥5.0 µg/ml for IFX (area under the curve of 0.92; 95% CI: 0.82-1.00)) and 5.9 µg/ml for ADL (area under the curve of 0.89; 95% CI 0.71-1.00) were associated with fistula closure.

Conclusion

Cut-off serum concentrations ≥5.0 µg/ml for IFX and ≥5.9 µg/ml for ADL were associated with perianal fistula closure. Hence, patients with producing perianal fistulas may benefit from anti-TNF dose intensification to achieve fistula closure.

Для цитирования: Strik Anne S, Löwenberg Mark, Buskens Christianne J, B Gecse Krisztina, I Ponsioen Cyriel, Bemelman Willem A, D'Haens Geert R. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.. Scandinavian journal of gastroenterology. 2019. DOI: 10.1080/00365521.2019.1600014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.